Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Biogen, Inc. (NQ: BIIB)
299.39 USD  +9.87 (+3.41%)
Official Closing Price  /  Updated: 7:59 PM EST, Dec 5, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 5,989,400
Open 291.00
Bid (Size) 297.02 (1)
Ask (Size) 298.98 (3)
Prev. Close 289.52
Today's Range 275.04 - 309.06
52wk Range 215.77 - 344.00
Shares Outstanding 211,007,945
Dividend Yield N/A
Performance
YTD
-1.74%
-1.74%
1 Month
+2.47%
+2.47%
3 Month
+33.68%
+33.68%
6 Month
+33.45%
+33.45%
1 Year
-8.36%
-8.36%
Top News
More News
Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)
from GlobeNewswire News Releases
Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response
Biogen Inc's(NASDAQ: BIIB) presentation of aducanumab data at the Clinical Trials On Alzheimer's Disease Congress has ... Read More
category alzheimer's , Trading Ideas , Cowen , and 13 more.
from Benzinga
More News
Read More
Mike Khouw Highlights Unusual Options Activity In Biogen
category Markets , Media , Market News , and 6 more.
from Benzinga
Biogen stock climbs as investors shrug off analyst skepticism about Alzheimer’s drug
category General , BIIB , Pharmaceuticals , and 10 more.
from MarketWatch
UPDATE 1-Novartis R&D boss says doesn't see big opportunity in oral SMA therapy
category companyNews
from Reuters: Company News
Biogen to make case to skeptics for its controversial Alzheimer's drug
category companyNews
from Reuters: Company News
Biogen Stock Popped: Here's What Happened In Its Alzheimer's Update
from Investor's Business Daily
Pharmacy benefits manager Abarca inks discount deal for Amgen's Enbrel
category companyNews
from Reuters: Company News
Cramer Weighs In On Biogen, Caterpillar And More
category CNBC , CAT , mad money Lightning Round , and 10 more.
from Benzinga
Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade
category ESALY , Benzinga , Biotech , and 11 more.
from Benzinga
Astellas’ $3 billion gene therapy deal steadies investors after stalled Roche acquisition
category GILD , M&A , BOLD , and 15 more.
from MarketWatch
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.